Allan Trial: Impact of Early Home-Based Palliative Care on Emergency Care in Advanced GI Cancer

Exploratory framing of the ALLAN trial's secondary outcomes: design, signals, and context

The study enrolled ambulatory adults with advanced GI cancers who were candidates for first-line palliative chemotherapy (upper GI: esophageal, gastric, hepatobiliary, pancreatic; lower GI: colorectal for second-line).

Eligibility included WHO performance status 0–2.

Exclusion criteria encompassed prior enrollment in SPC, ongoing palliative chemotherapy (except certain colorectal cancer cases), and neuroendocrine tumors.

The central question for this secondary analysis was whether early integration of home-based specialized palliative care (SPC) alongside tumour-directed treatment could influence emergency care utilization and related inpatient metrics compared with standard oncologic care with SPC access only on referral.

• This report presents secondary outcomes from a randomized controlled trial (ALLAN) conducted at a tertiary cancer center in southern Sweden.

The first SPC contact occurred within six weeks of randomization, followed by at least monthly SPC contacts.

The SPC team delivered comprehensive home-based care, including 24/7 availability for home consultations, and admission to inpatient care when necessary.

The home-based SPC provided capabilities for intravenous fluids, antibiotics, blood products, and nutritional support as part of advanced symptom and care management.

The SPC team employed systematic symptom assessment and monitoring, integrated with oncologic care, including concurrent evaluation of oncologic side effects and coordination with the treating oncologist.

Practical data elements captured included the number of SPC contacts, home visits, and telephone interactions with the SPC team, drawn from original medical records.

Blood sampling and radiology procedures could be arranged by the SPC team to support clinical decisions, reflecting a proactive, integrated approach to symptom management and treatment toxicity.

Data collection for patients in this arm focused on emergency department visits, hospitalizations, days of inpatient care, and inpatient SPC use, as derived from medical records traceable from trial inclusion.

• In the active arm, patients initiated tumour-directed therapy with early, structured involvement of a multidisciplinary SPC team.
• In the control arm, patients continued with standard oncologic care for tumour-directed treatment, with SPC involvement limited to referral when deemed necessary, i.e., a reactive model.

• Primary outcomes for this report were secondary to QoL outcomes reported earlier.

For the active arm, the SPC documentation also contributed to characterizing home-based care interactions.

• Number of emergency department visits
• Number of hospitalizations
• Length of inpatient care (days)
• Time from the last chemotherapy treatment to death
• Place of death
• Data sources included medical records, with the trial specifying that information on emergency visits and inpatient care started from the time of trial inclusion.

The article notes that the study was nonblinded and took place over a recruitment window spanning December 18, 2014, to April 29, 2021, with last follow-up on March 1, 2023.

The catchment area included two major SPC units serving roughly half a million residents, reflecting a real-world, regional implementation setting.

Although the exact numerical baseline characteristics are not reproduced here, the trial design emphasizes comparable populations between arms at initiation.

Key finding in the secondary outcomes: impact on emergency and inpatient utilization

Contextualizing these secondary findings within the broader literature and trial rationale

The trial’s design acknowledges that specialist palliative care, delivered early and in a home-based format, could potentially alleviate symptom burdens, reduce anxiety and distress, and improve QoL when combined with cancer-directed therapies.

In the context of this study, early home-based SPC was hypothesized to reduce acute health care utilization reflecting improved symptom management and less aggressive care toward the end of life.

The current secondary analysis validates that signal with objective healthcare utilization metrics.

• A total of 118 patients were randomized in the ALLAN trial.
• Baseline data reported include age, sex, cancer diagnosis category (upper vs lower GI), performance status, chemotherapy regimens, dates of randomization, date of last chemotherapy, and date of death.
• The primary signal of the secondary analysis demonstrated marked reductions in health care utilization for the early SPC integration group:
• Emergency department visits: median 1 in the early SPC group versus median 3 in the control group; this difference reached statistical significance (p < 0.001).
• Hospitalizations: median 1 in the early SPC group versus median 2 in the control group; this difference was also statistically significant (p < 0.001).
• Inpatient care days: median 1.5 days in the early SPC group versus 11.5 days in the control group; the reduction was highly significant (p < 0.001).
• Secondary clinical timelines and destinations:
• Time from last chemotherapy to death: no significant difference between groups.
• Inpatient SPC involvement: no significant difference in the use of inpatient SPC between arms.
• Place of death: no significant difference observed between groups.
• Taken together, early integration of home-based SPC alongside tumour-directed therapy in advanced GI cancer reduced reliance on emergency and inpatient hospital services without altering the general timing to death or the location of death.
• The ALLAN trial builds on a broader body of work recognizing that palliative care often appears as end-of-life (EoL) care and is frequently introduced late in the disease course.
• Prior evidence cited by the investigators supports the notion that integrating SPC with disease-directed treatment can mitigate disease- and treatment-related symptoms, and improve QoL relative to treatment alone.
• The article references related observational and randomized evidence from other cancers and palliative care paradigms:
• Retrospective and prospective studies indicate that longer duration of palliative care involvement before death correlates with fewer emergency department visits and hospitalizations, less likelihood of dying in hospital, and extended time from last palliative chemotherapy to death.
• However, a Cochrane review cited by the authors reported no conclusive evidence that home-based palliative care reduces unplanned hospital admissions for end-of-life care, highlighting ongoing uncertainty in this domain.
• Other cancer types, such as metastatic NSCLC, have shown reductions in chemotherapy administration near end of life with early SPC integration, suggesting a broader potential for alignment of palliative care with curative- or disease-directed strategies to possibly modulate end-of-life care intensity.
• The ALLAN trial’s reported QoL improvements in its primary report support the broader hypothesis that early SCP involvement yields patient-perceived benefits, of which reduced emergency and inpatient utilization may be a component or correlate.

They also acknowledge the broader literature’s mixed conclusions on home-based SPC and unplanned hospital admissions, underscoring the need for cautious interpretation and further research.

• The article notes several limitations inherent to the design and reporting of secondary outcomes:
• The trial is nonblinded, which could introduce performance or measurement biases in the management or documentation of care-seeking behavior and hospital utilization.
• Although reductions in emergency and inpatient utilization were statistically significant, the absence of significant differences in time-to-death and place-of-death suggests that early SPC did not alter terminal trajectories in these dimensions within the study period and population.
• The generalizability of findings may be constrained to similar healthcare systems and SPC structures, given the regional, unit-based configuration in southern Sweden.
• The authors emphasize that the reported outcomes are secondary to QoL and serve to contextualize the observed QoL improvements with objective service utilization data.

This signal aligns with a model of care that emphasizes continuous symptom management, rapid escalation of supportive therapies at home, and closer coordination between oncology and palliative teams, potentially translating into less acute care utilization.

The reductions in emergency and inpatient utilization may imply cost and resource implications, though the report does not provide economic data.

The absence of differences in death-related timelines and place of death suggests that while hospital-based demand is reduced, terminal care goals may require additional alignment with patient preferences and end-of-life planning.

• The main practical takeaway from the secondary outcomes is that early, proactive home-based SPC integrated with oncologic care is associated with decreased reliance on emergency department services and reduced inpatient hospital days among patients with advanced GI cancer receiving palliative chemotherapy.
• The approach used in the ALLAN trial underscores several operational elements:
• Early scheduling of SPC involvement within six weeks of randomization and maintaining at least monthly follow-up.
• Availability of 24/7 home-based SPC contacts and the capacity to provide intravenous therapies and supportive measures in the home setting.
• A multidisciplinary SPC team capable of symptom assessment, pain and side-effect management, nutrition and functional supports, and coordination with imaging or laboratory services to inform treatment decisions.
• For centers contemplating implementation, the ALLAN design illustrates a feasible structure for integrating SPC early in the cancer care pathway, with an emphasis on home-based delivery and robust collaboration with oncologists.

These factors influence the external validity and transportability of findings to other populations and health systems.

The report does not present numerical values for baseline characteristics or effect sizes beyond medians for the key secondary outcomes, nor does it provide confidence intervals or hazard ratios for these metrics within the excerpt.

The statistical significance is reported as p < 0.001 for the differences in ED visits, hospitalizations, and inpatient days, but exact interquartile ranges, population medians, or distributional details are not included here.

It is unclear whether certain subgroups derived greater benefit in terms of reduced emergency or inpatient use, or whether safety considerations differed by diagnosis or comorbidity burden.

However, this particular article refrains from extrapolating beyond the observed secondary outcomes and refrains from offering efficacy conclusions beyond the data presented.

• The study’s interpretive scope is constrained to: (1) the specific GI cancer population enrolled, (2) palliative chemotherapy as the treatment context, (3) the Swedish healthcare environment with its SPC infrastructure, and (4) a nonblinded trial design.
• The data described are strictly related to the frequency and duration of emergency department encounters, hospital admissions, and inpatient days.
• The analysis does not reveal subgroup differences by cancer subtype, performance status, or line of therapy beyond the reported aggregate results.
• The authors note ongoing or prior studies that report QoL improvements with early SPC and broaden the interpretive framework.

The current report does not include economic analyses, so future work could examine whether decreased acute care utilization translates into overall cost savings or reallocation of resources.

• Given the observed reductions in emergency care and inpatient hospitalization, a natural question concerns the cost-effectiveness of early home-based SPC in advanced GI cancer within similar health system contexts.
• Additional research could investigate whether specific components of home-based SPC (e.g., timely symptom management, home IV therapies, rapid escalation protocols, caregiver support, or telehealth modalities) differentially drive reductions in ED visits or hospitalizations, enabling optimization of SPC models.
• Further studies might explore patient-centered outcomes beyond QoL, such as caregiver burden, satisfaction with care, and alignment with patient preferences regarding place of death, particularly when SPC is initiated early and delivered at home.
• Comparisons across diverse geographic settings and health care systems would help determine the generalizability of the ALLAN trial’s observed reductions in urgent and inpatient utilization and clarify the conditions under which early SPC yields the greatest benefit.